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ABSTRACT
The epidermal growth factor receptor (EGFR) is often
overexpressed or dysregulated in a variety of solid tu-
mours, including gastrointestinal (GI) malignancies.
Agents targeting the EGFR-mediated signalling path-
way are increasingly part of the therapeutic armamen-
tarium for the treatment of advanced lung, head-and-
neck, and colorectal carcinoma. The EGFR inhibitors
(EGFRIs) approved in Canada include the tyrosine ki-
nase inhibitors erlotinib and gefitinib (in selected cases),
and the monoclonal antibodies (mAbs) panitumumab
and cetuximab. Although EGFRIs have been proven ef-
fective in the treatment of a variety of malignancies,
the entire class of agents is associated with a high
prevalence of dermatologic side effects, most com-
monly skin rash. This reversible condition requires in-
tervention in approximately one third of patients. A
proactive, multidisciplinary approach to management
can help to improve skin rash and optimize clinical
outcomes by preventing EGFRI dose reduction or dis-
continuation. In addition, effective management and
patient education may help to alleviate the significant
social and emotional anxiety related to this manage-
able side effect, thus resulting in improved quality of
life. The present article focuses on EGFR-targeted mAbs
for the treatment of GI malignancy, addressing the
pathophysiology, clinical presentation, and incidence
of skin rash caused by this class of agents. Recom-
mendations aimed at establishing a framework for con-
sistent, proactive management of skin rash in the
Canadian setting are presented.
KEY WORDS
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1. INTRODUCTION
The epidermal growth factor receptor (EGFR) is a trans-
membrane glycoprotein that is expressed in many
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normal human cells of epithelial origin, playing an im-
portant role in cell growth, differentiation, and prolif-
eration. The receptor consists of an extracellular
ligand-binding domain, a transmembrane region, and
an intracellular tyrosine kinase domain 1.
In many solid tumours, including most
gastrointestinal (GI) malignancies, EGFR is overex-
pressed 2. Dysregulated EGFR may result in uncon-
trolled cell growth, proliferation, and angiogenesis, and
is associated with a poorer prognosis, manifested by
increased metastatic potential and poorer overall sur-
vival (OS) times 3. Thus, EGFR is an ideal target for
antitumour therapy. Inhibitors of this target can be
broadly classified as either tyrosine kinase inhibitors
(TKIs) or monoclonal antibodies (mAbs), both of which
can produce significant skin toxicity.
The EGFR-blocking TKIs have been the subject of
several publications on skin rash, and therefore the
present article focuses on management of rash result-
ing from EGFR-targeted mAbs for the treatment of GI
malignancy. Although the management of rash caused
by TKIs and mAbs is clinically similar, there are dif-
ferences between these two classes of EGFR-targeted
agents with regard to the incidence, severity, and onset
of this skin toxicity.
2. EGFR-TARGETED MONOCLONAL
ANTIBODIES
The EGFR-targeted mAbs are given intravenously and
act by binding the extracellular domain, thus blocking
ligand binding and tyrosine phosphorylation. In Canada,
two mAbs have been approved for the treatment of
metastatic colorectal cancer (mCRC): cetuximab and
panitumumab (Table I).
Cetuximab (Erbitux: Bristol–Myers Squibb,
Princeton, NJ, U.S.A.) is a recombinant human/mouse
(chimeric) immunoglobulin G1 mAb that is adminis-
tered once weekly. Cetuximab in combination with
irinotecan (Camptosar: Pfizer Canada, Kirkland, QC)
is indicated in Canada for the treatment of EGFR-ex-
pressing mCRC in patients who are refractory to other
irinotecan-based chemotherapy regimens. It is also in-
dicated as monotherapy for EGFR-expressing mCRC inMELOSKY et al.
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patients with intolerance to irinotecan-based chemo-
therapy 4.
Panitumumab (Vectibix: Amgen Canada,
Mississauga, ON) is a fully-human immunoglobulin
G2 mAb administered once every 2 weeks.
Panitumumab is indicated as monotherapy for patients
with EGFR-expressing mCRC and with non-mutated
[wild-type (WT)] KRAS after disease progression on
fluoropyrimidine-, oxaliplatin-, and irinotecan-contain-
ing chemotherapy regimens 5. Panitumumab became
available in Canada in summer 2008 and was added to
the Ontario provincial drug program in November 2008.
2.1 Efficacy of EGFR-Targeted mAbs for Third-
Line Therapy of Advanced Colorectal
Malignancy
The EGFR-targeted mAbs have demonstrated efficacy
in the treatment of advanced colorectal malignancy in
a number of clinical trials (Table II).
In a randomized phase III study of chemotherapy-
refractory mCRC, panitumumab monotherapy almost
halved the risk of disease progression as compared with
progression in a best supportive care (BSC) control group
[hazard ratio (HR): 0.54; 95% confidence interval (CI):
0.44 to 0.66; p < 0.0001]. No significant difference was
observed in OS, likely because of the high percentage
(76%) of BSC patients who crossed over to panitumumab
at disease progression. Objective response was ob-
served in 10% of patients randomized to panitumumab
and in 11% of patients crossing over to this agent, as
compared with 0% in the BSC group 9.
A retrospective analysis of the phase III study ex-
amined the influence of KRAS mutation status on the
therapeutic efficacy of panitumumab. That analysis re-
ported that progression-free survival (PFS) was signifi-
cantly greater in patients with WT KRAS than in patients
with a mutant gene (p < 0.0001). Median PFS in WT
KRAS patients was 12.3 weeks for the panitumumab
group as compared with 7.3 weeks for the BSC group.
To account for potential tumour-ascertainment bias in
favour of the BSC arm, an interval-censored sensitivity
analysis was performed in which radiologic event times
were moved to the closest assessment time pre-speci-
fied in the study protocol. That analysis showed median
PFS times of 16 weeks and 8 weeks with panitumumab
and BSC respectively (HR: 0.44; 95% CI: 0.30 to 0.63).
No significant difference in OS was observed between
treatment arms for all patients (HR: 0.97; 95% CI: 0.79
to 1.18) or between KRAS groups (mutant gene—HR:
1.02; 95% CI: 0.75 to 1.39; WT gene—HR: 0.99; 95% CI:
0.75 to 1.29) 7. This report confirmed that, in terms of
PFS, the efficacy of panitumumab monotherapy for
mCRC is limited to patients with WT KRAS tumours.
Accordingly, KRAS mutation status must be evaluated
to optimize selection of patients with mCRC for
panitumumab monotherapy.
The efficacy of cetuximab monotherapy was evalu-
ated in a phase III National Cancer Institute of Canada
(NCIC) trial that randomized chemotherapy-refractory
mCRC patients to cetuximab monotherapy or BSC. Com-
pared with BSC alone, cetuximab treatment was asso-
ciated with significant improvements in PFS (HR: 0.68;
95% CI: 0.57 to 0.80; p < 0.001) and OS (HR: 0.77; 95%
CI: 0.64 to 0.92; p < 0.005). Median OS in the cetuximab
group was 6.1 months as compared with 4.6 months in
the BSC group 10. This NCIC trial did not allow crosso-
ver to active therapy for patients initially randomized
to receive BSC alone.
A Cox model analysis of the study examined the
predictive effect of KRAS mutation status on OS and
PFS. The authors reported that the effect of cetuximab
was significantly greater in the WT KRAS group than
in the mutant gene group both for PFS (p < 0.0001) and
for OS (p < 0.01). No significant difference in OS as a
function of KRAS status (WT vs. mutant) was observed
in the BSC arm (HR: 1.01; 95% CI: 0.74 to 1.37; p =
0.97). The authors concluded that KRAS mutation sta-
tus is a strong predictive biomarker and that mutation
analysis can be considered a new standard of care in
the selection of patients for EGFR-targeted therapy 8.
For this retrospective analysis, KRAS status was avail-
able for 69% of patients in the phase III cetuximab
monotherapy study as compared with 92% of the pa-
tients in the phase III panitumumab monotherapy analy-
sis discussed earlier 7,8.
Cetuximab plus irinotecan was studied in a
randomized phase II trial of third-line therapy for pa-
tients with mCRC: combination therapy was compared
with cetuximab alone. Median time to progression was
significantly greater in the combination arm (4.1
TABLE I   Health Canada–approved monoclonal antibodies targeting inhibitors of epidermal growth factor receptor
                   Agent Type Indication Dosing
Schedule
Cetuximab Mouse/human Third-line metastatic colorectal cancer, with or without irinotecan Once
chimeric IgG1 weekly
monoclonal antibody
Panitumumab Fully human Third-line metastatic colorectal cancer monotherapy Every
IgG2 second
monoclonal antibody week
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months) than in the monotherapy arm (1.5 months).
Tumour response rates (22.9% vs. 10.8%) and median
survival times were also significantly higher in the
combination arm than in the monotherapy arm 6.
2.2 Adverse Effects of EGFR Inhibition
The toxicity profile of EGFR-targeted mAbs excludes
many of the severe side effects commonly observed
with cytotoxic chemotherapy. As a class, however, EGFR
inhibitors (EGFRIs) are characterized by cutaneous ad-
verse effects, most commonly a papulopustular reac-
tion involving skin 11. Skin rash is mostly mild-to-
moderate in severity and requires therapeutic interven-
tion in about one third of patients 12. Although the skin
rash is self-limiting and usually resolves without scar-
ring upon discontinuation of anti-EGFR therapy 13, the
condition can negatively affect treatment compliance
and quality of life. In addition to leaving skin vulner-
able to bacterial overgrowth and serious infection, skin
rash can lead to dose modification or treatment dis-
continuation, thus potentially affecting the overall clini-
cal benefits of this form of therapy.
In a post-approval survey, 76% of respondents re-
ported holding EGFRIs at some point during therapy
because of skin rash, and up to 32% of physicians re-
ported discontinuing EGFRI treatment altogether 14.
Moreover, significant pain and pruritus, and anxiety
related to the cosmetic appearance of the rash can nega-
tively affect patient quality of life. Patients report that
stinging or burning, irritation, dry eyes, pain, and sleep
disturbances are the most significant symptoms 15.
Proactive strategies for the management of EGFRI-
mediated skin rash may help to maximize benefit for
patients by minimizing the negative effects on quality
of life and maintaining an optimal mAb dose.
The next section of this article reviews the patho-
physiology, clinical presentation, and incidence of skin
rash resulting from mAb therapy in colorectal cancer
and presents a practical treatment algorithm summa-
rizing recommendations—from a Canadian perspec-
tive—for the management of this skin toxicity. Also
addressed are the importance of proactive management,
the correlation between rash and efficacy of therapy,
and the direction of future research in this area.
3. PATHOPHYSIOLOGY, CLINICAL
PRESENTATION, AND INCIDENCE OF
SKIN RASH
3.1 Pathophysiology of mAb-Mediated Skin Rash
Epidermal growth factor receptor is normally expressed
in the epidermis, sebaceous glands, and hair follicular
epithelium 16, where it plays a number of important
roles in the maintenance of normal skin health, includ-
ing control of differentiation, protection against dam-
age induced by ultraviolet radiation, inhibition of
inflammation, and acceleration of wound healing 17.
Although the exact mechanism of skin rash mediated
by EGFR-targeted mAb is incompletely understood,
inhibition of EGFR is believed to cause follicular oc-
clusion and rupture because of premature epithelial
differentiation and an increase in the expression of
genes that stimulate inflammation, apoptosis, and cell
attachment 12,18 (Figure 1). This altered permeability
barrier may also allow for the promotion of bacterial
overgrowth 20, further exacerbating cutaneous injury
and development of the characteristic skin rash.
3.2 Description and Incidence of Skin Rash
Mediated by EGFR-Targeted mAb
Treatment with EGFRI is associated with a spectrum
of epidermal-derived toxicities. Although papulopus-
tular skin rash is the most common skin toxicity
TABLE II   Pivotal phase III and II trial results of monoclonal antibodies targeting inhibitors of epidermal growth factor receptor in patients
with third-line metastatic colorectal cancer
                Reference Regimens Progression-free survival (PFS) or Overall Response rate
time to progression (TTP) survival (RR)
Cunningham et al., 2004 6 Phase II Median TTP: 8.6 months (combination) Partial  RR:
cetuximab plus irinotecan 4.1 months (combination) 6.9 months (monotherapy) 22.9% (combination)
vs. cetuximab monotherapy, 1.5 months (monotherapy) p<0.01 10.8% (monotherapy)
all patients p<0.001 p<0.007
Amado et al., 2008 7 Phase III Median PFS: No significant difference Partial RR:
panitumumab monotherapy 12.3 weeks (panitumumab); (confounded by 17% (panitumumab),
vs. best supportive care 7.3 weeks (BSC) crossover design) 22% in crossover group;
(BSC) alone in patients p<0.0001 0% (BSC),
with wild-type KRAS p<0.0001 12% in crossover group
Karapetis et al., 2008 8 Phase III Median PFS: 9.5 months (cetuximab); Overall RR:
cetuximab monotherapy 3.8 months (cetuximab); 4.8 months (BSC) 12.8% (cetuximab);
vs. BSC alone 1.9 months (BSC) p<0.0001 0% (BSC)
in patients p<0.0001 p<0.001
with wild-type KRASMELOSKY et al.
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associated with EGFR-targeted mAbs (and the focus of
this article), other less frequent side effects can in-
clude dry skin, pruritus, fissures, palmar–plantar rash,
hyperkeratosis, telangiectasia, hyperpigmentation, blis-
ters, mucositis, and pyogenic granuloma. Changes may
also occur to the hair (for example, alopecia of the
scalp or trichomegaly of the eyelashes) and nails (usu-
ally periungual manifestations such as paronychia) 17,21.
In general, skin rash associated with the use of
EGFR-targeted mAbs tends to be more severe and to
occur with higher incidence than is observed with
TKIs. It also presents as a more purulent and pustular
reaction which may require more aggressive inter-
ventions 13. Skin rash has been reported in 80%–90%
of patients with mCRC treated with EGFR-targeted
mAbs as third-line therapy, with most cases being
mild-to-moderate in severity (Table III). The rash oc-
curs more frequently in areas of the face, neck, shoul-
ders, upper trunk, and scalp 17 and other sun-exposed
areas of the body 23.
3.3 Skin Rash Timeline
An EGFRI-mediated rash generally follows a well-char-
acterized clinical course (Figure 2). Within the first
week of treatment, patients experience sensory distur-
bance with erythema and edema. From weeks 1 to 3,
the papulopustular eruption manifests, followed by
crusting at week 4 25,26. Despite successful treatment,
erythema and dry skin may persist in the areas previ-
ously affected by the skin rash through weeks 4–6 27.
3.4 Manifestation of mAb-Induced Skin Rash
Based on phase III study experience, cetuximab-induced
skin rash appears to be dose-related 28 and generally
evolves within 1–3 weeks of the start of treatment for
mCRC 6. Panitumumab-associated rash also develops
within the first 3 weeks of treatment for mCRC, with a
median time of 14 days after start of therapy and a
median time to resolution of 84 days after the last
dose 9. Most patients with EGFRI-mediated skin rash
exhibit some degree of spontaneous partial improve-
ment during therapy, and the rash generally resolves
completely and without scarring following cessation
of the EGFR-targeted drug 13.
It is important to note that no association has been
observed between mAb-mediated skin rash and past
or pre-existing skin abnormalities such as acne or ro-
sacea 17,24. Additionally, terms such as “acne-like” or
“acneiform” to describe this unique rash are incorrect
and should be avoided, because histopathology does
not support this association 19,29.
3.5 Grading EGFRI-Mediated Skin Rash
Accurate grading of EGFRI-associated skin rash should
assist in optimizing treatment by allowing clinicians to
determine the most appropriate interventional strategy
for each patient. Data on the grading or severity of
EGFRI-mediated skin rash have been collected prima-
rily in clinical trials using the U.S. National Cancer
Institute’s Common Toxicity Criteria (NCI-CTC) ver-
sion 2.0 22 or its Common Terminology Criteria for
Adverse Events (NCI-CTCAE) version 3.0 30; however,
this system was designed as a broad surveillance tool
to monitor adverse events, and its usefulness for docu-
menting skin toxicities related to EGFRIs is question-
able 31. For example, the NCI-CTCAE relies heavily on
body surface area as a determinant of rash severity.
This approach fails to account for the location of EGFRI-
associated rash—generally confined to the face and
upper trunk—and also does not consider subjective
patient tolerability and discomfort.
An EGFRI-specific grading system, such as that
proposed by Pérez–Soler 29 (Figure 3), more accurately
TABLE III   Incidence of skin rash in pivotal phase III and II trials for monoclonal antibodies targeting inhibitors of epidermal growth factor
receptor in third-line metastatic colorectal cancer
                Reference Agent Regimen                                    Patients with skin rash (%)
Any gradea Grade 3 or 4a
Cunningham et al., 2004 6 Cetuximab With irinotecan 80 9
Van Cutsem et al., 2007 9 Panitumumab Monotherapy 90 14
Jonker et al., 2007 10 Cetuximab Monotherapy 89 12
a   Determined according to the U.S. National Cancer Institute’s Common Toxicity Criteria 22.
FIGURE 1   Pathophysiology of skin rash mediated by epidermal growth
factor receptor (EGFR) inhibition. (Adapted from Busam et al., 2001 19.)PRACTICE GUIDELINE SERIES
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reflects the specific nature of an EGFRI-mediated skin
rash, thus allowing clinicians to individually optimize
treatment. As well, such a grading system may pro-
vide a framework by which various therapeutic inter-
ventions may be compared, allowing optimal
management strategies to be identified.
4. REVIEW OF EXISTING
RECOMMENDATIONS ON THE
MANAGEMENT OF EGFRI-MEDIATED
SKIN RASH
4.1 Key Consensus Documents and Algorithms
Currently, the treatment of EGFRI-mediated skin rash
is based principally on qualitative evidence and anec-
dotal experience that have yet to be validated by well-
controlled randomized clinical trials. Yet, despite the
absence of level 1 evidence, a number of consensus
statements and algorithms 26,31–33 have been published
to share best practices with the common goal of mini-
mizing skin toxicities, improving quality of life, and
maximizing EGFRI treatment benefits by minimizing
the need for significant dose reductions (Table IV).
4.2 Proactive Management
In the clinical setting, up to 32% of physicians have
reported discontinuing, and 76% have reported hold-
ing, EGFRI treatment because of skin toxicity 14. Inter-
est in the development of primary pre-emptive
strategies has grown as recognition of the spectrum of
skin toxicity has evolved and so as to minimize dose
reduction or treatment discontinuation, which both po-
tentially compromise the clinical benefit of EGFRIs.
As a result, a small number of randomized controlled
trials have been designed to evaluate primary pre-
emptive strategies (Table V).
A controlled study called STEPP (Skin Toxicity
Evaluation Protocol with Panitumumab) is the first
prospective trial designed specifically to compare pri-
mary pre-emption with reactive treatment for EGFRI-
mediated skin toxicity 36. Patients receiving second-line
FOLFIRI (fluorouracil, leucovorin, irinotecan)–based
chemotherapy plus every-second-week panitumumab
(n = 32) or irinotecan-based chemotherapy plus
panitumumab every 3 weeks (n = 26) were randomized
to primary pre-emptive or reactive skin treatment. Pa-
tients randomized to the pre-emptive treatment arm
received daily skin treatment from 24 hours before their
first dose of panitumumab through week 6. Patients in
the reactive treatment arm received treatment after
development of skin toxicity. Skin toxicity treatment in
the pre-emptive arm included skin moisturizer, sun-
screen, 1% hydrocortisone cream, and doxycycline 100
mg twice daily. Treatment and timing of therapy ini-
tiation in the reactive arm were left to the discretion of
the investigator. Recently presented results indicated
that, as compared with reactive treatment, pre-emptive
treatment reduced the incidence of grade 2 or greater
skin toxicities by more than 50% without additional side
effects. In addition, time to severe skin toxicity was
significantly delayed in the pre-emptive treatment arm.
The time to first occurrence of any grade 2 or greater
skin toxicity was also significantly delayed in the pre-
emptive arm.
FIGURE 2   Characteristic phases of skin rash mediated by epidermal growth factor receptor (EGFR) inhibition. (From Lacouture et al., 2007 24.)MELOSKY et al.
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Two randomized double-blind trials have exam-
ined the effects of prophylactic skin rash treatment.
An 8-week trial studied prophylactic oral minocycline
as compared with placebo for patients with mCRC pre-
paring to initiate cetuximab therapy. Patients were also
randomized to receive topical tazarotene application
to the left or right side of the face. At weeks 1–4 of
mAb treatment, the minocycline group (n = 24) had a
significantly lower total facial lesion count and a sig-
nificantly reduced incidence of moderate-to-severe itch
as compared with the placebo group (n = 24, p = 0.05).
Study authors also concluded that topical tazarotene
was not recommended for the management of
cetuximab-mediated rash because it provided no clinical
benefit and was associated with significant skin irrita-
tion 34. In another double-blind trial, patients starting
EGFRI therapy were randomized to tetracycline (500
mg twice daily) or to placebo for 4 weeks (n = 61).
Although tetracycline did not prevent EGFRI-induced
rash, a reduction in rash severity was observed. At week
4, grade 2 rash was reported in 17% of the tetracycline
group and in 55% of the placebo group (p = 0.04).
Treatment also improved certain SKINDEX-16 quality-
of-life measures, including skin burning or stinging and
skin irritation 35.
Additional well-controlled prospective clinical tri-
als are needed to further examine the potential ben-
efits of primary pre-emption of EGFRI-mediated skin
toxicities, and to establish a framework for consistent
evidence-based treatment approaches based on biologic
mechanisms. In addition, further evaluation of patient,
nursing, and physician education tools is important and
may aid in the promotion of prophylactic intervention,
early recognition, and best practices in skin toxicity
management, thereby maximizing potential clinical ben-
efit from the EGFRI class of agents, reducing the risk of
serious infection, and improving patient quality of life.
4.3 Rash-to-Survival Correlation
Available retrospective evidence suggests that the ap-
pearance and severity of skin rash is positively corre-
lated with objective tumour response to EGFRI therapy
and with OS in mCRC. Data suggest that skin rash may
serve as a surrogate marker of EGFR-targeted mAb ef-
ficacy. In several analyses, both the presence and inten-
sity of skin toxicity predicted objective tumour response
in patients treated with cetuximab or panitumumab in
mCRC. In patients receiving cetuximab monotherapy for
refractory mCRC, longer survival times were observed
in patients with rash of any grade as compared with
patients experiencing no rash (p = 0.02) 37. In the piv-
otal phase II trial of cetuximab in combination with
irinotecan as compared with cetuximab alone in patients
with mCRC, response rates in patients with skin reac-
tion were higher than rates in patients without skin re-
action (25.8% vs. 6.3% in the combination group, 13.0%
vs. 0% in the monotherapy group; p = 0.005) 6.
Similar results have been observed in phase II and
phase III studies of panitumumab. An exploratory
analysis of the pivotal phase III trial of panitumumab
for third-line therapy of mCRC observed a positive
FIGURE 3   Modified grading system for skin rash mediated by epidermal growth factor receptor (EGFR) inhibition. (Adapted from Pérez–Soler
et al., 2005 29.)PRACTICE GUIDELINE SERIES
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correlation between increasing rash severity and im-
proved OS (Figure 4) 9. In a phase II study of
panitumumab in mCRC, patients with grades 2–4 maxi-
mum skin toxicity had improved PFS (HR: 0.67; 95%
CI: 0.50 to 0.90) and OS (HR: 0.72; 95% CI: 0.54 to
0.97) as compared with patients experiencing grades
0–1 skin toxicity 38. These observations were con-
firmed in a phase III open-label study in which im-
proved PFS was observed for patients with grades 2–4
as compared with grade 1 skin toxicity 39.
Overall, these observations support the consensus
that patients with mCRC receiving EGFRIs who develop
skin rash should be treated for the rash while continu-
ing EGFR-targeted mAbs, because these patients may
derive the greatest clinical benefit from therapy. Note
that these observations have yet to be validated by pro-
spective trials, and it should not be assumed that EGFR-
targeted mAbs are ineffective in patients who do not
develop rash.
4.4 Dose-to-Rash Studies
Retrospectively observed rash-to-survival correlations
suggest that individualized dose titration based on the
appearance and severity of skin rash may allow for
optimization of EGFRI therapy and have led to the ini-
tiation of “dose-to-rash” trials (increasing the dosage
until rash is observed) that are examining dose esca-
lation protocols. The phase I/II dose escalation trial in
patients with mCRC with no or slight skin reactions on
standard-dose cetuximab treatment, also known as the
EVEREST trial, supports the rash-to-survival correla-
tion, with prospective data demonstrating an increase
in rash severity and response rate with escalating dose
of cetuximab 40. Patients with mCRC with no or slight
skin reactions after 22 days of standard cetuximab
therapy were randomized to continue receiving a
standard dose or to begin a dose escalation protocol
that involved increasing the dose every 2 weeks until
a grade 2 skin toxicity or a cetuximab dose of 500
mg/m2 was achieved. As compared with the stand-
ard-dose arm, the dose-escalation arm demonstrated
an improvement in response rate (risk ratio: 30% vs.
13%). This finding supports the relationship between
tumour response rate, EGFRI dose, and skin toxicity,
thereby substantiating the correlation between EGFRI
activity at the level of the EGFR receptor on the skin
and in the tumour.
TABLE IV   Summary of selected consensus-derived publications for the management of skin rash mediated by inhibitors of epidermal growth
factor receptor (EGFRI)
       Reference                                                                      Description
Segaert et al., 2005 32 Consensus-derived manuscript and treatment algorithm developed by dermatologists, gastroenterologists,
and oncologists at a European consensus conference on EGFRI skin toxicity held in 2004 in Brussels, Belgium
Lacouture et al., 2006 33 Treatment approach, algorithm, and subspecialty clinic (SERIES) for the treatment of cutaneous and ocular
EGFRI toxicities; developed by hematologists, oncologists, ophthalmologists, and dermatologists meeting in
2005 in Chicago, Illinois
Eaby et al., 2008 26 and Two interdisciplinary consensus statements featuring a 3-tiered grading system for decision-making and
Lynch et al., 2007 31 stepwise intervention for skin toxicities; developed following a multidisciplinary forum attended by
oncologists, nurses, pharmacists, and dermatologists in 2006 in Chicago, Illinois
TABLE V    Summary of randomized double-blind trials evaluating primary preventive treatment strategies for skin toxicity mediated by
inhibitors of epidermal growth factor receptor (EGFRI)
      Reference Population Treatment Effect of preventive treatment
Scope et al., 2007 34 Patients with 8 Weeks prophylactic minocycline Significantly fewer total facial lesion counts;
metastatic colorectal cancer vs. placebo significantly reduced moderate-to-severe itch;
preparing to initiate topical tazarotene associated with significant irritation
cetuximab
Jatoi et al., 2008 35 Patients starting therapy 4 Weeks of prophylactic tetracycline Significant reduction in rash severity;
with EGFRI vs. placebo improved patient-reported SKINDEX-16 measures
of skin burning or stinging and skin irritation
Mitchell et al., 2008 36 Patients with 6 Weeks of pre-emptive treatment Significantly reduced incidence
metastatic colorectal cancer vs. reactive treatment of grade 2 or greater skin toxicities;
preparing to initiate with moisturizer, sunscreen, significantly delayed time to severe skin toxicity;
panitumumab hydrocortisone cream, significantly improved event-free probability
and doxycycline for grade 2 or greater skin toxicityMELOSKY et al.
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Although the mechanism underlying the correla-
tion between skin toxicity and tumour response is cur-
rently unclear, investigators have hypothesized that the
rash may be a surrogate marker for degree of receptor
saturation by the EGFRI agent. Accordingly, research-
ers have speculated that skin toxicity may aid in pre-
dicting which patients may preferentially or maximally
benefit from EGFRI therapies. In addition, targeting
doses to achieve a desired level of cutaneous toxicity
may further increase the efficacy of EGFRIs. Ongoing
and planned dose-to-rash studies will further evaluate
the potential benefit of dose escalation for patients with
mCRC and no or mild skin toxicity from EGFR-targeted
mAbs. If these studies confirm a relationship between
EGFRI dose and response rate, definitive studies using
PFS as an endpoint will be justified 12.
5. CANADIAN RECOMMENDATIONS FOR
MANAGEMENT OF EGFRI-MEDIATED
SKIN RASH
Given that anti-EGFR mAbs have demonstrated survival
advantages in second- and third-line therapy of mCRC,
the use of these agents continues to increase. Forthcom-
ing randomized clinical trial results will also determine
whether these agents are efficacious in the first-line
setting. As the use of these agents expands in Canada, a
better understanding of the associated skin toxicities and
optimal patient management strategies is becoming in-
creasingly important and remains a significant area of
new educational need for many clinical oncologists,
oncology nurses, and general practitioners.
5.1 General Pre-emption and Treatment Principles
The treatment strategies that follow are recommended,
based on consensus, for pre-emption and management
of mAb-mediated skin rash and other dermatologic
toxicities associated with these agents.
￿ Patients should be advised to take appropriate sun
protective measures, because sun-exposure can ex-
acerbate rash severity on unprotected areas of the
body 23.
￿ Patients should also be counselled to avoid activi-
ties and skin care products that dry the skin. Ex-
amples include long, hot showers; alcohol-based
or perfumed products; and over-the-counter acne
medication. Greasy ointments should also be
avoided in favour of frequent moisturizing with
alcohol-free emollient creams.
￿ For symptomatic relief, oatmeal baths can be sooth-
ing and are likely anti-inflammatory 41.
￿ Creams are more effective than lotions, and when
kept cool (for example, refrigerated), they can pro-
vide symptomatic benefit.
5.2 Skin Rash Treatment Recommendations
Specific Canadian treatment recommendations are
presented below according to grade of skin toxicity
(Figure 5). Grades 1, 2, and 3 reflect skin toxicity that
is mild, moderate, and severe respectively (adapted
from NCI-CTC). Although this grading system is pri-
marily intended for skin rash on the face and scalp, the
same grading can be applied to truncal rash, dry skin,
pruritus, and nail or periungual changes.
￿ Topical 2% clindamycin is recommended for mild-
to-severe skin rash, because this antibiotic has dem-
onstrated favourable results, including a drying
effect, on inflammatory pustules mediated by
EGFRI therapy 42.
￿ The use of a low- to medium-potency topical ster-
oid such as 1% hydrocortisone in a lotion base fur-
ther enhances treatment of mild-to-severe rash by
inhibiting inflammation 25.
￿ For moderate-to-severe skin toxicity, the oral semi-
synthetic tetracycline antibiotics minocycline or doxy-
cycline are recommended in addition to the topical
treatments already described. Although EGFRI-me-
diated skin toxicity does not seem to involve infec-
tious agents, the anti-inflammatory properties of the
tetracyclines, via matrix metalloproteinase inhibition,
may explain their effectiveness 43,44.
￿ Overall, management of skin rash should be indi-
vidualized for each patient, depending on the type,
severity, and location of the skin toxicity caused
by anti-EGFR therapy.
￿ Importantly, several situations warrant patient re-
ferral to a dermatologist. Clinicians may wish to
refer if the skin toxicity does not improve within 1–
2 weeks of treatment. Referral is also recommended
if the patient is severely symptomatic (for exam-
ple, if necrosis, blistering, or petechial or purpuric
lesions are present) or if multiple hair, nail, and skin
issues emerge 29. In general, if the skin toxicity has
an uncharacteristic appearance or distribution (it just
doesn’t look “right” or familiar), it is advisable to
refer the patient to a dermatologist.
FIGURE 4   Overall survival by severity of skin rash in patients with
third-line metastatic colorectal cancer receiving panitumumab. (From
Van Cutsem et al., 2007 9.)PRACTICE GUIDELINE SERIES
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FIGURE 5   Treatment recommendations for rash mediated by monoclonal antibody (mAb) targeting of epidermal growth factor receptor, by
severity. (Adapted from the BC Cancer Agency’s EGFR inhibitors rash protocol.) o.d. = once daily; b.i.d. = twice daily.MELOSKY et al.
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6. SUMMARY
Skin rash is a predictable but manageable side effect
of anti-EGFR therapy, including therapy with the EGFR-
targeted mAbs cetuximab and panitumumab. A
proactive, multidisciplinary approach to pre-emption
and therapy of skin toxicities will help to limit the inci-
dence of severe symptoms, improve patient tolerance
of therapy, maximize quality of life, and optimize clini-
cal benefits of EGFR-targeted mAbs by minimizing the
need for dose reduction or early treatment discontinu-
ation. The Canadian treatment recommendations and
algorithm presented in this article represent the cur-
rent consensus-derived best practice for treatment of
skin rash mediated by EGFR-targeted mAbs in patients
with mCRC, and they are likely generalizable to other
diseases being treated with these agents. Although well-
designed prospective trials remain necessary to con-
firm best practices, educational tools such as this
algorithm may serve to guide health care profession-
als and to inform patients with the goal of maximizing
the benefits of EGFRI therapy. Establishing evidence-
based approaches to the treatment of skin toxicities
will become an even greater priority as the indications
for these agents expand into earlier treatment and
adjuvant settings for mCRC and other tumour types.
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